View ValuationNeuren Pharmaceuticals 将来の成長Future 基準チェック /66Neuren Pharmaceuticals利益と収益がそれぞれ年間44.5%と32%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に36.5% 49.2%なると予測されています。主要情報44.5%収益成長率49.20%EPS成長率Pharmaceuticals 収益成長14.6%収益成長率32.0%将来の株主資本利益率36.50%アナリストカバレッジGood最終更新日27 May 2026今後の成長に関する最新情報お知らせ • Aug 28Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.すべての更新を表示Recent updatesお知らせ • Apr 25Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2026Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2026. Location: racv city club, level 2, bayside 4a/b, 501 bourke st, melbourne vic 3000 Australiaお知らせ • Apr 24Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025. Location: the event centre, level 5, tower 2, 727 collins st, melbourne vic 3000 Australiaお知らせ • Feb 27Neuren Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Neuren Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Feb 28, 2025お知らせ • May 28Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins SyndromeNeuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core characteristics of PTHS. There are no approved treatments for PTHS despite its severely debilitating impact on the lives of patients, as well as their parents and siblings. The open label Phase 2 trial in 16 children aged 3 to 17 years (mean age 9 years) at five hospitals in the United States examined safety, tolerability, pharmacokinetics and efficacy over 13 weeks of treatment with NNZ-2591. NNZ-2591 was administered to all subjects as an oral liquid dose twice daily, with escalation in two stages up to the target dose of 12 mg/kg during the first 6 weeks of treatment, subject to independent review of safety and tolerability data. The study commenced with at least 4 weeks of screening and observation to thoroughly define baseline characteristics prior to treatment, followed by the treatment period of 13 weeks. A follow-up assessment was made 2 weeks after the end of treatment. The primary endpoints of this first trial in children with PTHS were safety, tolerability and pharmacokinetics. Secondary endpoints included four efficacy measures specifically designed for PTHS assessed by clinicians and by caregivers, as well as ten efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. NNZ-2591 was well tolerated and demonstrated a good safety profile. All Treatment Emergent Adverse Events (TEAEs) were mild to moderate and most were considered not related to study drug. There were no Serious TEAEs and no meaningful trends in laboratory values, electrocardiogram (ECG) or other safety parameters were observed during treatment. 11 subjects completed the trial. One subject discontinued because they were unable to complete the safety monitoring procedures required by the study protocol. Four subjects discontinued due to TEAEs, all of which resolved. For two of those subjects the TEAEs (COVID-19 and mild vomiting/diarrhea/lethargy) were considered not related to study drug and for two subjects the TEAEs (moderate constipation/self-injury/abdominal distention/fatigue and mild sleep disorder/constipation) were considered related to study drug. The mean improvement from baseline was statistically significant (Wilcoxon signed rank test p<0.05) for each of the four efficacy measures that were specifically designed for Pitt Hopkins syndrome, whether calculated for the subjects that completed the study (n=11), or including discontinued subjects (n=15). Changes from baseline were not statistically significant for the efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. The results for the global measures rated by both clinicians and caregivers showed a level of improvement considered clinically meaningful. 9 out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Improvement (CGI-I), an assessment by the clinician of the child's overall status compared with baseline. The mean CGI-I score was 2.6. Five children received a score of either 1 ("very much improved") or 2 ("much improved"). 8 out of 11 children that completed the trial showed improvement measured by the PTHS Caregiver Overall Impression of Change (CIC), an assessment by the caregiver of the child's overall status compared with baseline. The mean CIC score was 3.0. Four children received a score of 2 ("much improved"). out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Severity (CGI-S), an assessment by the clinician of the child's overall severity of illness, compared with the assessment at baseline. The CGI-S score improved from 6 to 5 for 3 children and from 5 to 4 for 3 children. 8 out of 11 children that completed the trial showed improvement measured by the Caregiver Top 3 Concerns overall score, an individualised assessment by the caregiver of their child's most concerning symptoms. Language/Communication was the most commonly chosen concern.お知らせ • Apr 28Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024, at 14:30 E. Australia Standard Time. Location: FB Rice, Level 33 477 Collins St, Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the annual report of the Company; to Re-Election of Patrick Davies as a Director; to consider Auditor Fees and Expenses.お知らせ • Feb 29Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024Neuren Pharmaceuticals Limited announced that they will report Q4, 2023 results on Feb 29, 2024お知らせ • Aug 28Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.お知らせ • Aug 25Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023Neuren Pharmaceuticals Limited announced that they will report first half, 2023 results on Aug 28, 2023お知らせ • Jan 23Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDANeuren Pharmaceuticals Limited announced that the US Food and Drug Administration (FDA) has reviewed Neuren's Investigational New Drug (IND) application for NNZ-2591 in Prader-Willi syndrome (PWS) and given approval for Neuren to proceed with the planned Phase 2 clinical trial in children with PWS. Neuren is developing NNZ-2591 for four serious neurological disorders that emerge in early childhood. Phase 2 trials are currently ongoing in children with each of Angelman, Phelan-McDermid and Pitt Hopkins syndromes, for which there are no approved medicines. All four programs have been granted Orphan Drug designation by the FDA. Neuren previously reported positive results in the Magel2-null mouse model of Prader-Willi syndrome, in which treatment with NNZ-2591 for 6 weeks normalized fat mass, insulin levels, IGF-1 levels and all behavioural deficits.お知らせ • Sep 23Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 TrialsNeuren Pharmaceuticals Limited has initiated the manufacture of NNZ-2591 to supply the planned Phase 2 clinical trials. The contract manufacturer that supplied drug substance for the ongoing Phase 1 trial will carry out this larger scale manufacturing campaign. Neuren plans to commence Phase 2 trials in patients with each of Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome in 2021. Neuren has received Orphan Drug esignation from the FDA for NNZ-2591 to treat all three of these debilitating disorders that currently have no approved medicines.お知らせ • Aug 06Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million.Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 153,972 Price\Range: AUD 1.4お知らせ • Jul 08Neuren Pharmaceuticals Limited announced that it has received AUD 20.000012 million in fundingOn July 6, 2020, Neuren Pharmaceuticals Limited (ASX:NEU) closed the transaction. The company issued 14,285,723 shares for gross proceeds of AUD 20,000,012.2 in the transaction.お知らせ • Jun 30Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20 million in fundingNeuren Pharmaceuticals Limited (ASX:NEU) announced a private placement of 14,285,714 common shares at AUD 1.40 per share for gross proceeds of AUD 20,000,000 on June 29, 2020. The transaction will include participation from institutional and sophisticated investors in Australia, New Zealand, Hong Kong and the United Kingdom. The company expects to close the transaction on July 6, 2020.業績と収益の成長予測OTCPK:NURP.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028159175224168412/31/2027147583232412/31/202674141415412/31/20256530125125N/A9/30/202514290131131N/A6/30/2025219149138138N/A3/31/20252181466363N/A12/31/2024217142-11-11N/A9/30/20242061305454N/A6/30/2024195117119120N/A3/31/2024214137152152N/A12/31/2023232157185185N/A9/30/2023155106120120N/A6/30/202378555454N/A3/31/202347282929N/A12/31/202215044N/A9/30/20229-3-3-3N/A6/30/20223-7-10-10N/A3/31/20223-7-10-10N/A12/31/20213-8-10-10N/A9/30/20212-10-10-10N/A6/30/20211-12-9-9N/A3/31/20211-11-9-9N/A12/31/20201-9-8-8N/A9/30/20201-8-9-9N/A6/30/20200-8-9-9N/A3/31/20200-9-10-10N/A12/31/20190-11-12-12N/A9/30/20197-6N/A-5N/A6/30/201914-1N/A2N/A3/31/2019141N/A4N/A12/31/2018143N/A6N/A9/30/201873N/A0N/A6/30/201813N/A-6N/A3/31/201813N/A-6N/A12/31/201713N/A-6N/A9/30/20172-2N/A-7N/A6/30/20173-8N/A-8N/A3/31/20173-10N/A-10N/A12/31/20163-12N/A-12N/A9/30/20162-14N/A-14N/A6/30/20160-15N/A-17N/A3/31/20161-14N/A-15N/A12/31/20152-13N/A-13N/A9/30/20152-11N/A-11N/A6/30/20153-9N/A-8N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NURP.Fの予測収益成長率 (年間44.5% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: NURP.Fの収益 ( 44.5% ) はUS市場 ( 17% ) よりも速いペースで成長すると予測されています。高成長収益: NURP.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: NURP.Fの収益 ( 32% ) US市場 ( 11.8% ) よりも速いペースで成長すると予測されています。高い収益成長: NURP.Fの収益 ( 32% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NURP.Fの 自己資本利益率 は、3年後には高くなると予測されています ( 36.5 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 15:16終値2026/05/11 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neuren Pharmaceuticals Limited 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Melissa BensonBarrenjoey Markets Pty LimitedThomas WakimBell PotterElyse ShapiroCanaccord Genuity7 その他のアナリストを表示
お知らせ • Aug 28Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.
お知らせ • Apr 25Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2026Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2026. Location: racv city club, level 2, bayside 4a/b, 501 bourke st, melbourne vic 3000 Australia
お知らせ • Apr 24Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025. Location: the event centre, level 5, tower 2, 727 collins st, melbourne vic 3000 Australia
お知らせ • Feb 27Neuren Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Feb 28, 2025Neuren Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Feb 28, 2025
お知らせ • May 28Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins SyndromeNeuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core characteristics of PTHS. There are no approved treatments for PTHS despite its severely debilitating impact on the lives of patients, as well as their parents and siblings. The open label Phase 2 trial in 16 children aged 3 to 17 years (mean age 9 years) at five hospitals in the United States examined safety, tolerability, pharmacokinetics and efficacy over 13 weeks of treatment with NNZ-2591. NNZ-2591 was administered to all subjects as an oral liquid dose twice daily, with escalation in two stages up to the target dose of 12 mg/kg during the first 6 weeks of treatment, subject to independent review of safety and tolerability data. The study commenced with at least 4 weeks of screening and observation to thoroughly define baseline characteristics prior to treatment, followed by the treatment period of 13 weeks. A follow-up assessment was made 2 weeks after the end of treatment. The primary endpoints of this first trial in children with PTHS were safety, tolerability and pharmacokinetics. Secondary endpoints included four efficacy measures specifically designed for PTHS assessed by clinicians and by caregivers, as well as ten efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. NNZ-2591 was well tolerated and demonstrated a good safety profile. All Treatment Emergent Adverse Events (TEAEs) were mild to moderate and most were considered not related to study drug. There were no Serious TEAEs and no meaningful trends in laboratory values, electrocardiogram (ECG) or other safety parameters were observed during treatment. 11 subjects completed the trial. One subject discontinued because they were unable to complete the safety monitoring procedures required by the study protocol. Four subjects discontinued due to TEAEs, all of which resolved. For two of those subjects the TEAEs (COVID-19 and mild vomiting/diarrhea/lethargy) were considered not related to study drug and for two subjects the TEAEs (moderate constipation/self-injury/abdominal distention/fatigue and mild sleep disorder/constipation) were considered related to study drug. The mean improvement from baseline was statistically significant (Wilcoxon signed rank test p<0.05) for each of the four efficacy measures that were specifically designed for Pitt Hopkins syndrome, whether calculated for the subjects that completed the study (n=11), or including discontinued subjects (n=15). Changes from baseline were not statistically significant for the efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. The results for the global measures rated by both clinicians and caregivers showed a level of improvement considered clinically meaningful. 9 out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Improvement (CGI-I), an assessment by the clinician of the child's overall status compared with baseline. The mean CGI-I score was 2.6. Five children received a score of either 1 ("very much improved") or 2 ("much improved"). 8 out of 11 children that completed the trial showed improvement measured by the PTHS Caregiver Overall Impression of Change (CIC), an assessment by the caregiver of the child's overall status compared with baseline. The mean CIC score was 3.0. Four children received a score of 2 ("much improved"). out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Severity (CGI-S), an assessment by the clinician of the child's overall severity of illness, compared with the assessment at baseline. The CGI-S score improved from 6 to 5 for 3 children and from 5 to 4 for 3 children. 8 out of 11 children that completed the trial showed improvement measured by the Caregiver Top 3 Concerns overall score, an individualised assessment by the caregiver of their child's most concerning symptoms. Language/Communication was the most commonly chosen concern.
お知らせ • Apr 28Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024, at 14:30 E. Australia Standard Time. Location: FB Rice, Level 33 477 Collins St, Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the annual report of the Company; to Re-Election of Patrick Davies as a Director; to consider Auditor Fees and Expenses.
お知らせ • Feb 29Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024Neuren Pharmaceuticals Limited announced that they will report Q4, 2023 results on Feb 29, 2024
お知らせ • Aug 28Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023Neuren Pharmaceuticals Limited reiterate net sales guidance for the third quarter of 2023. The company is reiterating net sales guidance for Third Quarter 2023 of USD 45 to USD 55 million.
お知らせ • Aug 25Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023Neuren Pharmaceuticals Limited announced that they will report first half, 2023 results on Aug 28, 2023
お知らせ • Jan 23Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDANeuren Pharmaceuticals Limited announced that the US Food and Drug Administration (FDA) has reviewed Neuren's Investigational New Drug (IND) application for NNZ-2591 in Prader-Willi syndrome (PWS) and given approval for Neuren to proceed with the planned Phase 2 clinical trial in children with PWS. Neuren is developing NNZ-2591 for four serious neurological disorders that emerge in early childhood. Phase 2 trials are currently ongoing in children with each of Angelman, Phelan-McDermid and Pitt Hopkins syndromes, for which there are no approved medicines. All four programs have been granted Orphan Drug designation by the FDA. Neuren previously reported positive results in the Magel2-null mouse model of Prader-Willi syndrome, in which treatment with NNZ-2591 for 6 weeks normalized fat mass, insulin levels, IGF-1 levels and all behavioural deficits.
お知らせ • Sep 23Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 TrialsNeuren Pharmaceuticals Limited has initiated the manufacture of NNZ-2591 to supply the planned Phase 2 clinical trials. The contract manufacturer that supplied drug substance for the ongoing Phase 1 trial will carry out this larger scale manufacturing campaign. Neuren plans to commence Phase 2 trials in patients with each of Phelan-McDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome in 2021. Neuren has received Orphan Drug esignation from the FDA for NNZ-2591 to treat all three of these debilitating disorders that currently have no approved medicines.
お知らせ • Aug 06Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million.Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 153,972 Price\Range: AUD 1.4
お知らせ • Jul 08Neuren Pharmaceuticals Limited announced that it has received AUD 20.000012 million in fundingOn July 6, 2020, Neuren Pharmaceuticals Limited (ASX:NEU) closed the transaction. The company issued 14,285,723 shares for gross proceeds of AUD 20,000,012.2 in the transaction.
お知らせ • Jun 30Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20 million in fundingNeuren Pharmaceuticals Limited (ASX:NEU) announced a private placement of 14,285,714 common shares at AUD 1.40 per share for gross proceeds of AUD 20,000,000 on June 29, 2020. The transaction will include participation from institutional and sophisticated investors in Australia, New Zealand, Hong Kong and the United Kingdom. The company expects to close the transaction on July 6, 2020.